The aim of this real-world, retrospective cohort study (with a historical control group) was to compare the effectiveness of IDegLira with that of intensified conventional insulin therapy (ICT) in people with inadequately controlled type 2 diabetes on OADs and/or GLP-1 RAs and/or basal insulin therapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.